Diagnostic Accuracy of 18F-FDG PET in Restaging Patients with Medullary Thyroid Carcinoma and Elevated Calcitonin Levels
暂无分享,去创建一个
S. Larson | J. Shah | M. Gönen | H. Schöder | R. Tuttle | A. Shaha | S. C. Ong | I. M. Tabangay-Lim | I. Doddamane | S. Patel
[1] S. Larson,et al. Diagnostic accuracy and prognostic value of 18F-FDG PET in Hürthle cell thyroid cancer patients. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[2] T. Higuchi,et al. Review of fluorine-18-2-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in the follow-up of medullary and anaplastic thyroid carcinomas. , 2005, Cancer control : journal of the Moffitt Cancer Center.
[3] S. Larson,et al. 2-[18F]Fluoro-2-Deoxyglucose Positron Emission Tomography for the Detection of Disease in Patients with Prostate-Specific Antigen Relapse after Radical Prostatectomy , 2005, Clinical Cancer Research.
[4] J. Moley,et al. Medullary thyroid carcinoma: Including MEN 2A and MEN 2B syndromes , 2005, Journal of surgical oncology.
[5] O. Mawlawi,et al. Performance characteristics of a newly developed PET/CT scanner using NEMA standards in 2D and 3D modes. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[6] J. Plukker,et al. Impact of 18F-Fluoro-2-Deoxy-D-Glucose Positron Emission Tomography (FDG-PET) in Patients with Biochemical Evidence of Recurrent or Residual Medullary Thyroid Cancer , 2004, Annals of Surgical Oncology.
[7] H. Schöder,et al. Positron emission imaging of head and neck cancer, including thyroid carcinoma. , 2004, Seminars in nuclear medicine.
[8] Tim Mulnix,et al. PET performance measurements for an LSO-based combined PET/CT scanner using the National Electrical Manufacturers Association NU 2-2001 standard. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[9] K S Panageas,et al. Statistical issues in analysis of diagnostic imaging experiments with multiple observations per patient. , 2001, Radiology.
[10] S. Larson,et al. Resistance of [18f]-fluorodeoxyglucose-avid metastatic thyroid cancer lesions to treatment with high-dose radioactive iodine. , 2001, Thyroid : official journal of the American Thyroid Association.
[11] J. Bredow,et al. Fluorine-18 fluorodeoxyglucose positron emission tomography in medullary thyroid cancer: results of a multicentre study , 2001, European Journal of Nuclear Medicine.
[12] Z. Szentirmay,et al. Angiography effectively supports the diagnosis of hepatic metastases in medullary thyroid carcinoma , 2001, Cancer.
[13] A. Abbruzzese,et al. Current approaches and perspectives in the therapy of medullary thyroid carcinoma , 2001, Cancer.
[14] A. Talei,et al. Medullary Thyroid Carcinoma , 2000, Acta Cytologica.
[15] O. Schober,et al. Fluorine-18 fluorodeoxyglucose positron emission tomography in thyroid cancer: results of a multicentre study , 1999, European Journal of Nuclear Medicine.
[16] B. Glaser,et al. Somatostatin receptor scintigraphy for early detection of regional and distant metastases of medullary carcinoma of the thyroid. , 1999, Clinical nuclear medicine.
[17] H. Oğuz,et al. Determination of medullary thyroid carcinoma metastases by 201Tl, 99Tcm(V)DMSA, 99Tcm-MIBI and 99Tcm-tetrofosmin. , 1999, Nuclear medicine communications.
[18] I. Fleming,et al. A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985‐1995 , 1998, Cancer.
[19] X. Matías-Guiu,et al. Use of somatostatin analogue scintigraphy in the localization of recurrent medullary thyroid carcinoma , 1998, European Journal of Nuclear Medicine.
[20] K. Usadel,et al. Limited value of fluorine-18 fluorodeoxyglucose positron emission tomography for the imaging of neuroendocrine tumours , 1997, European Journal of Nuclear Medicine.
[21] J. Moley,et al. Evaluation of fluorodeoxyglucose-positron emission tomographic scanning and its association with glucose transporter expression in medullary thyroid carcinoma and pheochromocytoma: a clinical and molecular study. , 1997, Surgery.
[22] D. Marsh,et al. Medullary thyroid carcinoma: recent advances and management update. , 1995, Thyroid : official journal of the American Thyroid Association.
[23] T. Lairmore,et al. Medullary carcinoma of the thyroid: current diagnosis and management. , 1991, Seminars in surgical oncology.
[24] A. Miyauchi,et al. Relation of Doubling Time of Plasma Calcitonin Levels to Prognosis and Recurrence of Medullary Thyroid Carcinoma , 1984, Annals of surgery.
[25] M. Girelli,et al. Nonparallel patterns of calcitonin and carcinoembryonic antigen levels in the follow‐up of medullary thyroid carcinoma , 1984, Cancer.
[26] A. Tashjian,et al. Calcitonin and carcinoembryonic antigen as tumor markers in medullary thyroid carcinoma. , 1978, American journal of clinical pathology.
[27] P. Ágoston,et al. 18F-FDG PET detection of lymph node metastases in medullary thyroid carcinoma. , 2002, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[28] P. Ágoston,et al. 18F-FDG PET detection of lymph node metastases in medullary thyroid carcinoma. , 2002, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[29] E. Nitzsche,et al. 18F-DOPA positron emission tomography for tumour detection in patients with medullary thyroid carcinoma and elevated calcitonin levels , 2001, European Journal of Nuclear Medicine.
[30] A. Bockisch,et al. The value of fluorine-18 fluorodeoxyglucose PET in patients with medullary thyroid cancer. , 2000, European journal of nuclear medicine.
[31] C. Bekdik,et al. Comparison of 99mTc(V)-DMSA, 201Tl and 99mTc-MIBI imaging in the follow-up of patients with medullary carcinoma of the thyroid. , 1996, European journal of nuclear medicine.